SIRPA and neoplasm: Currently, by blocking CD47-signal regulatory protein α (SIRPα) signaling, restoring phagocytosis of tumor cells by macrophages, and promoting the response of effector CD8+ T cells, tumor cell proliferation and metastasis are effectively inhibited [116].